A major cancer research advocacy organization wants key House lawmakers to include in their upcoming Cures 2.0 package a policy that would give FDA authority to require generic drug labels be updated to reflect new information about the drug and its use. The request is one of several proposals Friends of Cancer Research (FOCR) includes in a letter to House Energy & Commerce oversight subcommittee Chair Diana DeGette (D-CO) and Rep. Fred Upton (R-MI) on areas to include in the...